破发连亏股东亚药业遭责令改正 A股两募资共15.7亿元

Core Points - Zhejiang Dongya Pharmaceutical Co., Ltd. has been ordered to rectify its fundraising practices due to discrepancies between the actual use of funds and the disclosures made in its initial public offering prospectus [1][5][6] - The company reported a significant decline in revenue and net profit for the first half of 2025, with a revenue of 416 million yuan, down 35.85% year-on-year, and a net loss of approximately 30.23 million yuan [1] - Dongya Pharmaceutical's stock is currently trading below its initial offering price, indicating a state of underperformance since its listing [2] Fundraising and Financial Performance - The company raised a total of 884 million yuan during its IPO, with a net amount of 782 million yuan allocated for various projects, including the production of key intermediates and raw materials for antibiotics [2][4] - In 2024, Dongya Pharmaceutical's revenue was 1.198 billion yuan, a decrease of 11.66% year-on-year, with a net loss of 101 million yuan, reflecting a 183.02% decline compared to the previous year [1] - The company has conducted two fundraising rounds since its listing, totaling 1.574 billion yuan [4]